These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10971177)

  • 21. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
    Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hormonal therapy for endometrial adenocarcinoma].
    Susumu N; Aoki D; Suzuki N; Nozawa S
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):934-45. PubMed ID: 11478142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral high-dose medroxyprogesterone acetate treatment for recurrent breast cancer.
    Iino Y; Takeo T; Sugamata N; Aoyagi H; Takai Y; Takei H; Ando T; Koibuchi Y; Yokoe T; Ohwada S
    Anticancer Res; 1995; 15(3):1061-4. PubMed ID: 7645926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA].
    Sonoo H; Senoo T; Nishiki M; Morimoto T; Takashima S
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):447-54. PubMed ID: 8678496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
    Muss HB; Case LD; Atkins JN; Bearden JD; Cooper MR; Cruz JM; Jackson DV; O'Rourke MA; Pavy MD; Powell BL
    J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients.
    Etienne MC; Milano G; Frenay M; Renee N; Francois E; Thyss A; Schneider M; Namer M
    J Clin Oncol; 1992 Jul; 10(7):1176-82. PubMed ID: 1535103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medroxyprogesterone acetate and cancer cachexia: interleukin-6 involvement.
    Yamashita JI; Ogawa M
    Breast Cancer; 2000; 7(2):130-5. PubMed ID: 11029784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group.
    Kloke O; Klaassen U; Oberhoff C; Hartwich G; Szanto J; Wolf E; Heckmann M; Huhn R; Stephan L; Schnepper U; Donsbach GM; Bechtel C; Rudolph R; Berke A; Borquez D; Hawig I; Hirche H; Schindler AE; Seeber S; Becher R
    Breast Cancer Res Treat; 1999 May; 55(1):51-9. PubMed ID: 10472779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
    Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
    J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer.
    Palmieri D; Halverson DO; Ouatas T; Horak CE; Salerno M; Johnson J; Figg WD; Hollingshead M; Hursting S; Berrigan D; Steinberg SM; Merino MJ; Steeg PS
    J Natl Cancer Inst; 2005 May; 97(9):632-42. PubMed ID: 15870434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007.
    Miller KD; Althouse SK; Nabell L; Rugo H; Carey L; Kimmick G; Jones DR; Merino MJ; Steeg PS
    Breast Cancer Res Treat; 2014 Nov; 148(1):99-106. PubMed ID: 25257727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate.
    Mantovani G; Macciò A; Lai P; Massa E; Ghiani M; Santona MC
    Semin Oncol; 1998 Apr; 25(2 Suppl 6):45-52. PubMed ID: 9625383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of tamoxifen and high-dose medroxyprogesterone acetate (MPA) on cell-mediated immune functions in breast cancer patients.
    Mallmann P; Dietrich K; Krebs D
    Methods Find Exp Clin Pharmacol; 1990 Dec; 12(10):699-706. PubMed ID: 2151629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
    Nomura Y; Tashiro H; Hisamatsu K; Toi M
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].
    Izuo M; Tominaga T; Yoshida M; Nomura Y; Abe O; Enomoto K; Kubo K; Takatani O
    Gan No Rinsho; 1985 May; 31(5):487-93. PubMed ID: 3160869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia.
    Downer S; Joel S; Allbright A; Plant H; Stubbs L; Talbot D; Slevin M
    Br J Cancer; 1993 May; 67(5):1102-5. PubMed ID: 8494706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical pharmacokinetics and practical consequences of optimal use of medroxyprogesterone acetate].
    Etienne MC; Milano G; Namer M
    Bull Cancer; 1993 May; 80(5):431-8. PubMed ID: 8173196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial.
    Focan C; Beauduin M; Salamon E; de Greve J; de Wasch G; Lobelle JP; Majois F; Tagnon A; Tytgat J; van Belle S; Vandervellen R; Vindevoghel A;
    Br J Cancer; 2001 Jul; 85(1):1-8. PubMed ID: 11437394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer].
    Kadota K; Wada T; Watatani M; Houjou T; Mori N; Yasutomi M
    Gan To Kagaku Ryoho; 1991 May; 18(6):983-7. PubMed ID: 1827574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefits of Medroxyprogesterone Acetate (MPA) in Advanced or Recurrent Breast Cancer with Higher Serum Concertration.
    Nishimura R; Nagao K; Matsuda M; Baba K; Matsuoka Y; Yamashita H; Fukuda M; Higuchi A; Saiki T
    Breast Cancer; 1995 Oct; 2(2):133-141. PubMed ID: 11091543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.